DSIP, short for Delta Sleep Inducing Peptide, is one of the more curious molecules to emerge from twentieth-century neuroscience. Researchers first isolated it in the 1970s from the blood of rabbits in deep sleep, and it has kept them occupied ever since. Despite the name, its role in the body appears to reach well beyond sleep, and a great deal of what we know remains provisional. This guide explains what DSIP Peptide is, where it came from, which research areas it appears in, and how laboratories handle it in practice. It is written for researchers, postgraduate students and technical buyers who want a clear reference point rather than marketing copy. DSIP is supplied strictly for laboratory research and is not approved for human or veterinary use anywhere in the world.
What Is DSIP?
DSIP is a small endogenous peptide, meaning the body produces it naturally. Its basic properties are straightforward:
- Length: nine amino acids, making it a nonapeptide
- Sequence: Trp Ala Gly Gly Asp Ala Ser Gly Glu, often written as WAGGDASGE
- Molecular weight: roughly 848 daltons
- Solubility: readily soluble in water, with no significant secondary structure
- Distribution: detected in brain tissue, plasma, the gastrointestinal tract, adrenal glands and other peripheral tissues in mammals, including humans.
A Short History of Its Discovery
The peptide was identified by Schoenenberger, Monnier and colleagues at the University of Bern in the mid 1970s. Their method was elegant in its simplicity. They took a dialysate of cerebral venous blood from rabbits in slow wave sleep, transferred it to recipient rabbits, and recorded an increase in delta wave activity on the recipients' electroencephalograms.
The name followed that single observation, which is worth stressing because the label has encouraged decades of overstatement. Calling something a sleep inducing peptide does not confirm that sleep induction is its main biological function.
How DSIP Is Thought to Work
No dedicated DSIP receptor has ever been identified, which is unusual for a peptide studied for fifty years. Current thinking treats it as a modulator rather than a direct agonist at any single target. Proposed mechanisms include:
- Influence on GABAergic and glutamatergic signalling in the central nervous system
- Modulation of hypothalamic and pituitary output, including ACTH, luteinising hormone and somatotropin
- Interaction with opioid and dopaminergic pathways in animal models
- Possible antioxidant activity in cell culture
Two practical points shape almost every study. DSIP is broken down rapidly by plasma peptidases, so its measured half life is very short, and whether much of it crosses the blood brain barrier remains contested.
Main Areas of Research Interest
Sleep and circadian rhythm
The original line of enquiry. Findings across rodent, rabbit and early human studies have been inconsistent, with some reporting altered sleep onset and architecture and others showing no measurable effect.
Stress and the hypothalamic pituitary adrenal axis
Several groups have examined whether DSIP dampens corticosteroid responses to stress. This is arguably the most reproducible signal in the literature, though effect sizes are modest.
Pain and nociception
Animal work has explored analgesic and antinociceptive properties, usually alongside opioid pathways.
Withdrawal, thermoregulation and oncology
Small clinical series from the 1980s examined opiate and alcohol withdrawal symptoms, and Anisimov and colleagues reported oncostatic and lifespan effects in rodents. Both lines are still cited, though neither has seen much independent replication.
Why the Evidence Base Is Still Thin
Anyone approaching DSIP for the first time should understand why a peptide this old still lacks firm conclusions:
- Most human studies were small, uncontrolled and predate modern trial standards
- Rapid enzymatic degradation makes pharmacokinetics hard to characterise
- Species differences in response are pronounced
- Reliable assays for endogenous concentrations were slow to develop
- The molecule is long out of patent, so there has been little commercial appetite for large trials
Handling and Storage in the Laboratory
Good practice with DSIP is much the same as with other short lyophilised peptides:
- Store sealed lyophilised vials in a freezer, protected from light and moisture
- Allow vials to reach room temperature before opening to reduce condensation
- Keep any prepared solution refrigerated and use it within a short window
- Avoid repeated freeze and thaw cycles, which degrade small peptides quickly
- Log the lot number and retain the certificate of analysis for every batch
The Legal Position in the United Kingdom
DSIP is not a controlled substance under the Misuse of Drugs Act 1971. It also holds no marketing authorisation from the MHRA, which means it is not a licensed medicine in the UK.
That produces a clear boundary. Supplying DSIP as a research chemical to laboratories and institutions is lawful, while selling, promoting or labelling it for human consumption is not. Animal work falls under the Animals (Scientific Procedures) Act 1986 and requires licensing and ethical approval. Competitive athletes should check the current WADA list with UK Anti-Doping rather than assume anything.
What to Look for in a Research Peptide Supplier
- Stated purity of 98 per cent or higher
- A batch specific certificate of analysis, not a generic template
- Accompanying HPLC chromatogram and mass spectrometry results
- Cold chain handling, insulated despatch and clear research use only labelling
- UK despatch, which avoids customs delays on temperature sensitive goods
- Technical staff who can answer questions about a specific lot
Conclusion
DSIP occupies an unusual position in peptide science. It has been known for half a century and is unquestionably present in mammalian tissue, yet its function is still a matter of reasonable debate. For researchers, that gap is the appeal. Solid work begins with a well characterised, properly documented reagent, because inconsistent starting material has already muddied enough of this literature.
If you are planning this line of work, Signal Peptide supplies research grade material with full batch documentation, verified purity and UK despatch. Contact our technical team with your specification and we will help you source exactly what your protocol requires.
For laboratory research use only. Not for human or veterinary use, and not for food, cosmetic or household purposes.
Frequently Asked Questions
Is DSIP the same as a sleeping tablet?
No. Sedatives such as benzodiazepines and Z drugs act directly on well characterised receptor targets and are licensed medicines. DSIP is an endogenous peptide with no confirmed receptor and no licence anywhere.
Can I buy DSIP legally in the UK?
Yes, for laboratory research. It is not a controlled drug, but it cannot lawfully be sold or supplied for human consumption because it has no marketing authorisation.
What purity should I expect?
Look for 98 per cent or better, evidenced by a batch specific certificate of analysis with HPLC and mass spectrometry data. Treat any supplier who cannot produce one with caution.
How long does DSIP remain stable?
Sealed lyophilised material stored frozen and dry is generally stable for a long period. Once in solution, stability drops sharply, so prepare small volumes and keep them refrigerated.
Has DSIP been proven to work in humans?
No. Human data is limited to small, mostly dated studies with mixed results. There is no approved therapeutic use for it in any jurisdiction.